Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.
about
Fluvoxamine versus other anti-depressive agents for depressionRecovery from prolonged cerebral depression after fluvoxamine overdoseUptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells.Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice.A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteersA double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine.Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders.Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing.Neuroendocrine studies with fluvoxamine: animal data.A double-blind controlled clinical trial comparing fluvoxamine with imipramineCardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine.A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depressionHigh performance liquid chromatographic determination of fluvoxamine in human plasma.Clinical and biochemical aspects of depressive disorders: III. Treatment and controversies.Determination of fluvoxamine concentration in plasma by reversed-phase liquid chromatography.Fluvoxamine and clomipramine in the treatment of cataplexy.Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis.Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine.Review of the animal pharmacology and pharmacokinetics of fluvoxamine.Effects of acute paroxetine administration on tryptophan metabolism and disposition in the rat.5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor.A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers.Circular dichroism spectroscopy and DFT calculations in determining absolute configuration and E/Z isomers of conjugated oximes.The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: role of monoamine oxidase in dopaminergic terminals.Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers.Human Beta Cells Produce and Release Serotonin to Inhibit Glucagon Secretion from Alpha Cells.Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.Fluvoxamine and clomipramine in depressed patients. A double-blind clinical study.Quantitative1H NMR spectroscopic determination of theE/Z isomer ratio of the antidepressant drug fluvoxamine for use in pharmaceutical analysis
P2860
Q24236814-166CF97E-B6F2-499A-B232-8179E1E999A3Q28361036-6C80F492-3F2A-434C-ABEA-DCDEDB572282Q33494732-8EECBA23-E195-4866-9F32-A732199B2584Q34354332-5B261DBA-1D19-481A-9E41-1231325B2E87Q34511940-2C2D861F-9B21-4130-9B96-C255A9EFF39EQ34511952-FBF2FABF-8187-4EE2-BB8F-2629A9C08A9BQ34511958-1BC5C604-EE9D-4A9A-8F8C-C9EA72D7485CQ34511966-B192ED89-9064-469B-8E57-CDE637F40917Q34511974-668C4920-A7A6-47CB-9221-6968F75F85D2Q34511981-147E39F3-0222-4EFF-849D-C31151088F5AQ34511988-EA97D15A-D9F4-4928-B3A6-BA93FDA3E8B6Q34511998-B83EE9A8-57F1-4853-B119-F645290BF878Q35224060-2F8672B2-D710-49D0-9E78-969B6E602DDCQ36106487-B45F0B99-A660-485E-AD0D-C407086628EFQ36719437-9CE9A48D-A9B9-4A70-8F92-C5DF47E2334DQ36997543-8D629FAE-2ED0-4F83-918E-11D0D9E75F78Q37194201-43944E66-6B63-48AA-AB69-A35D8F479E37Q37423099-776BB7E2-2026-4589-B7BF-6F8422650E2EQ40207565-740C68C4-F039-42BD-8B77-B6D397CDEC4EQ42560603-61E34F9D-9323-4FA4-92DD-70BE4D235534Q42849285-63FFB799-89DF-4C5B-B2D5-D92BEB96AB7BQ43087981-F94E9916-D1F9-4018-865A-0370FE8A0107Q48148541-D6D22D1D-9587-4591-888B-D3F69F0224EFQ48371652-C72D6368-54FC-44C0-B66C-3E324CCD3EC0Q48552713-1096BDFC-D0FF-4A8E-BA7D-67BC74329486Q48703814-B41DC29D-E7C7-4672-BFAA-864C11257D9AQ51240535-A822562D-20DF-4038-B4D5-D86CEE11A6F0Q51759464-65DB5D3F-7CBD-4F33-A545-655106D00B67Q51867128-585645D7-099A-4463-9D4D-00C499CA9F4BQ58856363-4BDDB7BF-D9A8-4B62-A54A-59D36FA08C5D
P2860
Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.
@en
type
label
Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.
@en
prefLabel
Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.
@en
P2093
P2860
P1476
Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.
@en
P2093
Claassen V
Hertting G
Placheta P
P2860
P304
P356
10.1111/J.1476-5381.1977.TB07528.X
P407
P577
1977-08-01T00:00:00Z